{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01454336",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Royan-liver-003"
      },
      "Organization": {
        "OrgFullName": "Royan Institute",
        "OrgClass": "OTHER_GOV"
      },
      "BriefTitle": "Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone",
      "OfficialTitle": "Phase 1 Trial of Combined Pioglitazone Plus Autologous Bone Marrow Mesenchymal Stem Cell Transplantation in Patients With Compensated Cirrhosis"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2010",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "June 2010"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "July 2013",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "July 2013",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "October 15, 2011",
      "StudyFirstSubmitQCDate": "October 18, 2011",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "October 19, 2011",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "May 10, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "May 13, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Royan Institute",
        "LeadSponsorClass": "OTHER_GOV"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Liver cirrhosis (LC) is the final destiny in chronic liver disease. Liver transplantation is the only effective therapy available to these patients. However, limited number of donors, post surgical complications, immunological rejection, and financial considerations are it's essential problems. The immuomodulatory impact of MSCs in fibrosis was confirmed, and several clinical studies have applied MSCs to eliminate the progression of fibrosis. In this research the investigators will study the affect of MSCs and Pioglitazone in the process of fibrosis.",
      "DetailedDescription": "BM Aspiration will be done twice (6 months interval) from the iliac crest according to standard procedures under general anesthesia and is collected (200ML) in plastic bags containing anti coagulant. After precipitation of red blood cells, mononuclear cells will be collected by centrifugation in Ficoll-Paque density gradient. MNCs will be cultured in T150 flasks. Cells will be expanded in several subcultures.MSCs will be injected (6 months interval) via portal vein under sonography monitoring.Each patient will receive 30mg Pioglitazone daily for 24 months. After cell therapy, patients are followed up every week for 6 months, and laboratory data are analyzed for 6 months."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Liver Fibrosis"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "MSCs",
          "Pioglitazon",
          "fibrosis",
          "liver"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "3",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Cirrhotic Patients",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "3 cirrhotic patients who underwent a combination of cell therapy and chemotherapy",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Cell injection"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Cell injection",
            "InterventionDescription": "MSCs introduced into portal vein",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Cirrhotic Patients"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "ALT",
            "PrimaryOutcomeDescription": "Evaluation of ALT levels during 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "AST",
            "PrimaryOutcomeDescription": "Evaluation of AST levels after intervention during 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Serum Albumin",
            "PrimaryOutcomeDescription": "The evaluation of serum albumin levels for 12 months",
            "PrimaryOutcomeTimeFrame": "12 months"
          },
          {
            "PrimaryOutcomeMeasure": "Liver Fibrosis",
            "PrimaryOutcomeDescription": "The decrease in grade of liver fibrosis",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Progression of fibrosis",
            "SecondaryOutcomeDescription": "Evaluation of fibrosis based on fibroscan and biopsy and scoring",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\n18-65 Years cirrhotic patient\nApproved cirrhosis by elastografy ,biopsy, sonography\n\nExclusion Criteria:\n\n1 - Portal vein thrombosis 2-Hepatic encephalopathy, score 3&4 3-ALT & AST 3times more than normal 4-Serum Cr more than 1/5mg/dL 5-(Anti-HIV +) (Anti-HCV+) (HBS-Ag+) 6-Hepatocel carcinoma 7- Primary sclerosing cholangitis (PSC) 8- Esophageal varices grade 4 9-Addiction 10-Child Score B,C",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "65 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Hamid Gourabi, PhD",
            "OverallOfficialAffiliation": "Head of Royan Institute",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Reza malekzadeh, MD",
            "OverallOfficialAffiliation": "Director of DDRC",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "Massoud vosough, MD,PhD",
            "OverallOfficialAffiliation": "Royan regenerative medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Royan Institute",
            "LocationCity": "Tehran",
            "LocationCountry": "Iran, Islamic Republic of"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000008103",
            "ConditionMeshTerm": "Liver Cirrhosis"
          },
          {
            "ConditionMeshId": "D000005355",
            "ConditionMeshTerm": "Fibrosis"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000010335",
            "ConditionAncestorTerm": "Pathologic Processes"
          },
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M7637",
            "ConditionBrowseLeafName": "Fibrosis",
            "ConditionBrowseLeafAsFound": "Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10255",
            "ConditionBrowseLeafName": "Liver Cirrhosis",
            "ConditionBrowseLeafAsFound": "Liver Fibrosis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M1693",
            "InterventionBrowseLeafName": "Pioglitazone",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Hypo",
            "InterventionBrowseBranchName": "Hypoglycemic Agents"
          }
        ]
      }
    }
  }
}